Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis

J Jiayu Wang (Jiangsu Engineering Laboratory of Novel Functional Polymeric Materials, Jiangsu Key Laboratory of Advanced Negative Carbon Technologies, Suzhou Key Laboratory of Soft Material and New Energy, College of Chemistry, Chemical Engineering and Materials Science, Soochow University) Q Qingyuan Zhang (Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, China) H Huiping Li Z Zhongsheng Tong Q Quchang Ouyang H Huihui Li (CAS Key Laboratory of Nanosystem and Hierarchical Fabrication) Y Yuee Teng B Biyun Wang T Tao Sun J Jingfen Wang W Wei Li Z Zhaofeng Niu H Hongsheng Li C Chang Gong S Shu Wang X Xinshuai Wang X Xinhong Wu N Ning Liu G Guohua Yu F Fei Liu X Xianghui Duan S Shuya Wang (Institute of Molecular Plus, Haihe Laboratory of Sustainable Chemical Transformations) Y Yaping Meng L Li Wang (The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou China) B Binghe Xu (Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing)